Keyphrases
Heart Failure
85%
Heart Failure with Preserved Ejection Fraction (HFpEF)
47%
Confidence Interval
34%
Patients with Heart Failure
33%
Coronary Artery Disease
32%
ST-elevation Myocardial Infarction (STEMI)
30%
Metformin
26%
Type 2 Diabetes Mellitus (T2DM)
25%
Left Ventricular Remodeling
20%
Meta-analysis
20%
Desmosine
20%
All-cause Mortality
18%
Left Ventricular Hypertrophy
17%
Placebo
17%
Heart Disease Diagnosis
15%
Ejection Fraction
15%
Hazard Ratio
14%
Diabetes
14%
Echocardiography
14%
Hypertension
14%
Late Gadolinium Enhancement
13%
Inflammation
13%
Acute ST-segment Elevation Myocardial Infarction
13%
Pathophysiology
13%
Chronic Heart Failure
13%
Beta-blockers
12%
Prognostic Significance
12%
Odds Ratio
12%
Endothelial Dysfunction
12%
Scotland
12%
Patients with Diabetes
12%
Cardiac Magnetic Resonance Imaging (cMRI)
11%
Population Cohort Study
11%
Electronic Health Records
11%
Exercise-based Cardiac Rehabilitation
11%
Intramyocardial Hemorrhage
10%
Type 2 Diabetic Patients
10%
Tayside
10%
Elastin
10%
Incident Heart Failure
10%
Heart Failure Hospitalization
10%
Heart Failure Treatment
9%
Incremental Prognostic Value
9%
Dapagliflozin
9%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
9%
Ruptured Abdominal Aortic Aneurysm (rAAA)
9%
Survivors
9%
Systematic Meta-analysis
9%
Major Adverse Cardiovascular Events
9%
Dilated Cardiomyopathy
9%
Medicine and Dentistry
Congestive Heart Failure
96%
ST Segment Elevation Myocardial Infarction
30%
Cardiovascular Disease
28%
Coronary Artery Disease
24%
Cardiac Magnetic Resonance Imaging
23%
Maturity Onset Diabetes of the Young
22%
Biological Marker
21%
Glycon
20%
Ejection Fraction
19%
Heart Failure with Preserved Ejection Fraction
18%
Cohort Analysis
17%
Myocardial Infarction
16%
Heart Failure with Reduced Ejection Fraction
16%
Diabetes
16%
Echocardiography
15%
Cardiovascular System
15%
Left Ventricular Hypertrophy
14%
Gadolinium
13%
Placebo
13%
Meta-Analysis
13%
Infarction
13%
Systematic Review
12%
Pathophysiology
12%
Heart Ventricle Remodeling
11%
Desmosine
11%
Electronic Health Record
11%
Ischemic Heart Disease
10%
Hazard Ratio
9%
Endothelial Dysfunction
9%
Patient with Diabetes
9%
Heart Rehabilitation
8%
Diseases
8%
Abdominal Aortic Aneurysm
8%
Aneurysm
8%
Bleeding
8%
Obstruction
7%
Atrial Fibrillation
7%
Heart Left Ventricle Ejection Fraction
7%
Odds Ratio
7%
Elastin
6%
Mendelian Randomization Analysis
6%
Patient with Type 2 Diabetes
6%
Coronary Angiography
6%
Diabetes Mellitus
6%
Cardiovascular Effect
6%
Loop Diuretic Agent
6%
Outpatient
6%
Kidney Function
6%
Dilated Cardiomyopathy
6%
Adipose Tissue
6%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
ST Segment Elevation Myocardial Infarction
32%
Cardiovascular Disease
24%
Metformin
20%
Placebo
20%
Heart Infarction
20%
Cohort Study
19%
Heart Failure with Reduced Ejection Fraction
18%
Biological Marker
18%
Non Insulin Dependent Diabetes Mellitus
18%
Heart Ventricle Remodeling
18%
Inflammation
15%
Desmosine
14%
Bleeding
12%
Heart Left Ventricle Hypertrophy
12%
Coronary Artery Disease
12%
Pathophysiology
12%
Endothelial Dysfunction
12%
Infarction
12%
Heart Failure with Preserved Ejection Fraction
11%
Diseases
10%
Elastin
9%
Cardiovascular Risk
9%
Abdominal Aortic Aneurysm
9%
Dapagliflozin
9%
Obstruction
9%
Loop Diuretic Agent
9%
Diabetes Mellitus
9%
All Cause Mortality
8%
Aneurysm
8%
Randomized Controlled Trial
8%
Ischemic Heart Disease
7%
Atrial Fibrillation
6%
Beta Adrenergic Receptor Blocking Agent
6%
Sodium Glucose Cotransporter 2 Inhibitor
6%
Cotransporter
6%
Diabetic Cardiomyopathy
5%
Acute Heart Infarction
5%
Diverticulosis
5%
Diverticulitis
5%
Nicorandil
5%
Genetic Risk
5%